GSK plc (NYSE:GSK) Shares Sold by Tweedy Browne Co LLC

Tweedy Browne Co LLC reduced its holdings in GSK plc (NYSE:GSK) by 13.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 93,816 shares of the pharmaceutical company’s stock after selling 14,219 shares during the quarter. Tweedy Browne Co LLC’s holdings in GSK were worth $3,173,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in GSK. Summit Financial LLC increased its stake in GSK by 45.2% during the 4th quarter. Summit Financial LLC now owns 7,128 shares of the pharmaceutical company’s stock worth $244,000 after buying an additional 2,218 shares during the period. Hoey Investments Inc. bought a new stake in GSK during the fourth quarter worth approximately $452,000. Wellington Management Group LLP lifted its holdings in GSK by 10.0% in the 4th quarter. Wellington Management Group LLP now owns 2,094,105 shares of the pharmaceutical company’s stock valued at $70,823,000 after acquiring an additional 190,047 shares during the last quarter. United Bank boosted its stake in shares of GSK by 22.0% during the 4th quarter. United Bank now owns 31,449 shares of the pharmaceutical company’s stock worth $1,064,000 after acquiring an additional 5,664 shares in the last quarter. Finally, Level Four Advisory Services LLC boosted its stake in GSK by 5.9% in the 4th quarter. Level Four Advisory Services LLC now owns 9,152 shares of the pharmaceutical company’s stock worth $310,000 after purchasing an additional 511 shares during the period. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Stock Performance

GSK stock opened at $38.81 on Tuesday. The company has a 50 day moving average price of $37.33 and a 200 day moving average price of $36.66. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The stock has a market capitalization of $80.33 billion, a PE ratio of 24.41, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.93.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Analysts forecast that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be paid a $0.3932 dividend. This is an increase from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. This represents a $1.57 annualized dividend and a dividend yield of 4.05%. GSK’s dividend payout ratio (DPR) is currently 98.74%.

Analyst Upgrades and Downgrades

GSK has been the subject of a number of recent research reports. Morgan Stanley began coverage on GSK in a research note on Wednesday, February 12th. They set an “equal weight” rating for the company. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.